Abstract |
A 67-year-old woman in poor general condition consulted my clinic with complaints of dyspnea and right chest wall pain. There was a huge and moist ulcer, caused by recurrence and post-radiation, on her right anterior to posterior chest wall. A chest X-ray demonstrated massive pleural effusion. Bone scinti gram showed multiple metastases in the spine, femur and pelvis. Her general condition was so poor that standard chemotherapy was unsuitable. Therefore, the patient was orally administered DMpC( doxifluridine, medroxyprogesterone acetate and cyclophosphamide)combination therapy. The pleural effusion had completely disappeared after 11 weeks, and the elevated serum CA15-3 and CEA value returned to a normal range 13 weeks later. No side effects were observed from this therapy. The patient clinically achieved good QOL in 6 months form this therapy with zoredronic acid administration. DMpC therapy appears to have few side effects and might be an effective treatment option for recurrent breast cancer patients with a poor general health condition.
|
Authors | Mikihiro Kusama |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 39
Issue 8
Pg. 1239-41
(Aug 2012)
ISSN: 0385-0684 [Print] Japan |
PMID | 22902449
(Publication Type: Case Reports, English Abstract, Journal Article)
|
Chemical References |
- Floxuridine
- Cyclophosphamide
- Medroxyprogesterone Acetate
- doxifluridine
|
Topics |
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Bone Neoplasms
(drug therapy, secondary)
- Breast Neoplasms
(drug therapy, pathology)
- Cyclophosphamide
(administration & dosage)
- Female
- Floxuridine
(administration & dosage)
- Humans
- Medroxyprogesterone Acetate
(administration & dosage)
- Pleural Neoplasms
(drug therapy, secondary)
- Quality of Life
- Recurrence
- Thoracic Wall
(pathology)
|